First‐in‐human study of JNJ‐67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome

First‐in‐human study of JNJ‐67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome

Abstract Relapsed/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) outcomes remain poor. A targeted cluster of differentiation (CD)33 × CD3 bispecific antibody, JNJ‐67571244, was assessed to identify the maximum tolerated dose (MTD), recommended phase II dose (RP2D),...

Full description

Bibliographic Details
Main Authors: Rupa Narayan, Ana Alfonso Piérola, William B. Donnellan, Antonieta Molero Yordi, Maher Abdul‐Hay, Uwe Platzbecker, Marion Subklewe, Tapan Mahendra Kadia, Juan Manuel Alonso‐Domínguez, James McCloskey, Kathryn Bradford, Martin Curtis, Nikki Daskalakis, Christina Guttke, Karim Safer, Brett Hiebert, Joseph Murphy, Xiang Li, Ken Duchin, Daniel Esteban
Format: Article
Language:English
Published: Wiley 2024-03-01
Series:Clinical and Translational Science
Online Access:https://doi.org/10.1111/cts.13742

Internet

https://doi.org/10.1111/cts.13742

Similar Items